Close Menu

NEW YORK (360Dx) – Genomic Health announced last week the full launch of what it calls the Oncotype DX AR-V7 Nucleus Detect test, an assay designed and performed by circulating tumor cell firm Epic Sciences.

The test detects the AR-V7 splice variant of the androgen receptor protein in the nucleus of isolated CTCs in order to identify which men with metastatic castration-resistant prostate cancer are more likely to respond to treatment with an androgen receptor-signaling inhibitor (ARSI) therapy, and which would be better served by chemotherapy.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.